Rosa & Co. Presents Results of 7 QSP Studies in 10th Consecutive Appearance at ACoP10

Rosa’s PhysioPD™ Research fundamentally improves decision making at critical steps in drug development.

These case studies show the value of PhysioPD Research, and our ability to reduce and front-load risk, which has had a transformative impact on the economics of drug development for our clients.”— Ron Beaver, Founder, Chairman and CEO of Rosa & Co.

SAN CARLOS, CA, USA, October 15, 2019 -- Results from seven studies presented at the Tenth American Conference on Pharmacometrics (ACoP10) demonstrate the value of Rosa & Co.’s brand of quantitative systems pharmacology (QSP) – PhysioPD Research – in increasing confidence and reducing risk in drug development. These studies demonstrate improved candidate selection, clarification of disease and drug mechanisms, and the use of PhysioPD Research to extrapolate clinical results from adults to children to reduce risk in pediatric drug development. More...

Rosa & Co. LLC is expanding and seeking scientists and modelers

Rosa & Co. LLC is expanding and seeking an Associate Life Scientist, a Senior Life Scientist, as well as a Biological Systems Modeler to join our PhysioPD™ consulting practice.

Rosa is a drug-disease modeling and simulation company created to provide innovative modeling solutions to its biopharmaceutical clients and meaningful equity ownership to its employees.

Life Scientists and Modeling Engineers work together in our PhysioPD practice to develop physiologically-based, dynamic mathematical models and conduct simulations of disease, drug action, and (pre)clinical studies.

Full and part-time employment and project-based contracting opportunities are available throughout the United States. Interested individuals should email their resume or CV and an introductory letter to hr@rosaandco.com.

Rosa is an equal opportunity employer. Upon hiring, proof of eligibility to work in the United States will be required.

For more information, download the attached .pdf file

Rosa & Co. Announces Strategic Research Agreement with Chugai Pharmaceutical Co., Ltd.

Rosa & Co. LLC, a drug development advisory firm known worldwide for its PhysioPD™ Research Platforms, today announced the initiation of a long-term Strategic Research Agreement with Chugai Pharmaceutical Co., Ltd. to provide Rosa’s PhysioPD research services.

The collaboration between Chugai and Rosa will provide Chugai a competitive research and development advantage across multiple therapeutic areas and throughout Chugai’s R&D pipeline, delivering unique scientific insights and actionable program recommendations, reducing risk and addressing complex and consequential decisions inherent in drug development.

“Chugai strives to develop hand in hand with society through creation of innovative drugs and services. I am convinced that Rosa’s novel platform will provide a powerful tool to transform our research into real innovation.” said Kimio Terao, Department Manager of the Clinical Pharmacology Department, Translational Research Division, in Chugai.

Rosa’s agreement with Chugai further extends Rosa’s position as the global market leader in PhysioPD Research, a Quantitative Systems Pharmacology (QSP) approach that translates biology into an interactive simulation platform representing physiology, disease, and intervention effects. It also reinforces the value that PhysioPD Research Platforms deliver through greater scientific insight and more informed drug discovery and development decisions.

“We are extremely pleased to extend our relationship with Chugai. Over the last several years we have been working with them on various projects and this agreement validates the value PhysioPD Research brings,” said Rosa Founder, Chairman, & CEO Ron Beaver, PhD. “Our Strategic Research Agreements are a particularly efficient means to achieve the benefits of PhysioPD Research on a portfolio-wide basis”.

About Rosa
Rosa & Co was established in 2002 and is known worldwide for its PhysioPD™ Research Platforms which elucidate the connection between disease mechanisms, therapeutic interventions, and clinical outcomes. PhysioPD Research delivers credible scientific insights and actionable program impact that would be difficult or impossible to achieve with any other research approach.

Pharmaceutical, biotechnology, and consumer goods clients realize significant return on investment when using PhysioPD Research for identifying responder patient populations, selecting predictive biomarkers, prioritizing or repurposing compounds, and predicting clinical efficacy of new targets. With decades of experience, 100+ presentations and publications, and mature business processes Rosa works effectively in complex organizational and scientific settings, ultimately helping clients reduce the risk of unsuccessful clinical trials or product submissions across their entire portfolio.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

Additional information is available on the internet at https://www.chugai-pharm.co.jp/english/

Quantitative Systems Pharmacology Pioneers

Long before the world knew what to call ‘Quantitative Systems Pharmacology’ (QSP) in the realm of preclinical and clinical drug development, Ron Beaver, Founder, Chairman, and CEO of Rosa & Co. already had his moment of revelation. He realized that deeper understanding of empirical data and effective learning about the connection of drug and disease mechanisms are critical for more informed decisions at all stages in research and development. Driven by his passion for enabling effective experimental and trial design, he founded Rosa in 2002 to deliver an increase in confidence and reduction in risk in pharmaceutical and consumer product research and development. Today, the company holds a unique spot as a global industry-leading pharmacology solution provider for its breadth and depth of understanding of this space.

Read more in Pharma Tech Outlook, Dec 2018: https://www.pharmatechoutlook....

Sanofi and Rosa to Present Research Results at the 2019 ASCPT Annual Meeting

Rosa & Co. LLC, an organization known worldwide for its PhysioPD™ Research Platforms, announced today that it will present two research posters at the 2019 ASCPT Annual Meeting Pre-Conference, “Advancing QSP Toward Predictive Drug Development: From Targets to Treatments,” in Washington, DC, March 13–17, 2019, in collaboration with Sanofi. The posters will address the use of QSP models in metabolic diseases as well as rheumatology research:

1) Incorporation of Renal SGLT Function into a Quantitative Systems Pharmacology (QSP) Model. M. Reed, M. Weis, R. Baillie, H.-C. Schneider, T. Klabunde


2) Evaluation of Novel Anti-TNFα and IL-6R Therapies in a Rheumatoid Arthritis (RA) Quantitative Systems Pharmacology Platform (QSP). V. Hurez, M. Weis, R. Baillie, M. Rehberg, K. Beuke, N. Biesemann, C. Asbrand, T. Klabunde, M. Herrmann, M. Reed

Meet us at the poster sessions on March 13 between 8 a.m.–5 p.m., or contact us to arrange a meeting at another time during the event.

Rosa & Co. to Present Research Results at the 2018 American Conference on Pharmacometrics

Rosa & Co. LLC, an organization known worldwide for its PhysioPD™ Research Platforms, announced today that it will present posters with Takeda Pharmaceutical Company Ltd, and Boehringer Ingelheim GmbH at the Ninth American Conference on Pharmacometrics (ACoP9) in San Diego, California, October 7–10, 2018. The poster presentations will describe research in a range of therapeutic areas, including immuno-oncology, neurology, and respiratory diseases:

On Monday Oct 8, in the morning, the research poster with Boehringer Ingelheim will be presented: "Development of the Respiratory PhysioPD™ Platform, a Quantitative Systems Pharmacology (QSP) Model, to Investigate Biological Mechanisms Underlying Bronchoconstriction".

On Tuesday, Oct 9, in the morning, Rosa will present: "Evaluation of the Efficacy of a CD122 Biased Agonist for Treatment of Melanoma as a Monotherapy and in Combination with PD-1 Inhibition Using a Mechanistic Physiological Model".

On Wednesday Oct 10, in the afternoon, the poster with Takeda will be presented: "Quantitative Systems Pharmacology Model to Quantify Benefits of DAO Inhibition in Schizophrenia".

When working with clients, we focus on giving them the tools to test hypotheses to make informed decisions about the disease pathophysiology, mechanism of action of the candidate drugs, and factors responsible for variability in the patient response,” said Rosa Founder, Chairman, and CEO Ron Beaver, PhD. “Using QSP and our PhysioPD™ Research Platform, we surface insights which help biopharma organizations to focus on most promising aspects of the drug efficacy and patient response.

The posters will be available at www.rosaandco.com/publications after the start of the ACoP9 meeting.

Grünenthal and Rosa to present at the 2018 SID/IID dermatology meeting

Dr. Katherine Kudrycki, Principal Scientist at Rosa & Co, will present "Evaluation of a novel therapy and identification of uncertainties critical to efficacy and competitive differentiation in a Psoriasis PhysioPD™ Platform. " at the 2018 SID/IID Dermatology meeting in Orlando, FL May 16-19, 2018.

Together with Grünenthal, Rosa & Co developed a Psoriasis QSP model to mechanistically represent the physiology of a single chronic psoriatic plaque (including keratinocytes, immune cells, cytokines and chemokines and their regulation), drug PK and clinical outcomes (e.g., PASI score). At the meeting Dr. Kudrycki will demonstrate how the model was qualified and used to get insights into the therapeutic potential and efficacy of novel small molecule enzyme-specific inhibitors.

For more information, contact Dr. Katherine Kudrycki at kkudrycki@rosaandco.com

Rosa & Co. is looking to hire a Senior Engineer, PhysioPD™

We are hiring! Rosa & Co. is looking for a Senior Engineer to work with scientists in our PhysioPD practice to develop mechanistic QSP models and conduct simulations of disease, drug action, and (pre)clinical studies. Download the .pdf for more information: https://www.rosaandco.com/uplo...

Dr. Christina Friedrich to present a webinar for the Committee on Credible Practice of Modeling & Simulation in Healthcare

The Committee on Credible Practice of Modeling & Simulation in Healthcare invited Rosa’s Chief Engineer, Dr. Christina Friedrich, to present a webinar on how to ensure model quality for Quantitative Systems Pharmacology (QSP) models. 

The committee, an initiative started by the Interagency Modeling and Analysis Group and Multiscale Modeling Consortium, aims to establish a task-oriented collaborative platform to outline good practice of simulation-based medicine.

On March 6 Dr. Friedrich's webinar introduced the concept of a Model Qualification Method (MQM) and presented two case studies to illustrate the utility of the method. 

The webinar was archived and is freely accessible at https://youtu.be/xk3_8DyoSPQ

Genentech and Rosa to present at the 2018 ASCPT Annual meeting

Genentech and Rosa will jointly present "Using a Quantitative Systems Pharmacology approach to investigate causes of the adverse GI events associated with prolonged treatment with PI3-Kinase inhibitors" at the 2018 ASCPT Annual meeting in Orlando, FL March 21-24, 2018. 

Happy Holidays from Rosa & Co

Happy holidays from all of us at Rosa & Co. 

Wishing you an amazing 2018!

Rosa & Co. is looking to hire a PhysioPD™ Engineer

Engineers work with Scientists in our PhysioPD practice to develop physiologically-based, dynamic mathematical models and conduct simulations of disease, drug action, and (pre)clinical studies.

Rosa & Co. Presents Record Number of Research Results at the Eighth American Conference on Pharmacometrics (ACoP8)

Rosa & Co., LLC announced today that they will be presenting a record 12 research posters and presentations at the eighth American Conference on Pharmacometrics (ACoP8), to be held in Fort Lauderdale, FL, on October 15–18, 2017.

Rosa to participate at the 32nd Annual meeting of the Japanese Society for the Study of Xenobiotics (JSSX)

Rosa & Co announced today that Mike Reed, Chief Scientist at Rosa, will be participating in the panel discussion “QSP in oncology – practical application, challenge and opportunity” at the 32nd Annual meeting of the Japanese Society for the Study of Xenobiotics.

Rosa to participate and present at the Insulin-Glucose Systems Pharmacology FDA workshop

Rosa & Co announced today that Mike Reed, Chief Scientist at Rosa, and Michael Weis, Senior Engineer at Rosa, will present “Diabetes models big and small – case examples from 15 years of scoping, developing, and qualifying fit-for-purpose models for QSP research to support drug development” at the Insulin-Glucose Systems Pharmacology FDA workshop in Washington, DC on August 17-18, 2017.

Rosa to present at the NIH Quantitative Systems Pharmacology and Neurotherapeutics Drug Discovery Workshop

Rosa & Co today announced that Dr. Meghan Pryor will be participating and presenting at the NIH Quantitative Systems Pharmacology and Neurotherapeutics Drug Discovery Workshop in Bethesda, MD, on July 26 – 27. Dr. Pryor will present a poster entitled “A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)”. The poster shows how the PGRN PhysioPD Research Platform has been proven to be useful to simulate the effects of modulating different targets and investigating drug effects on increasing PGRN for the treatment of FTD.

Rosa & Co. Announces Renewal of Multi-Year Research Agreement with Sanofi

Rosa & Co. LLC is pleased to announce the renewal of a multi-year Research Agreement with Sanofi to provide Rosa’s PhysioPD™ services. The continuing collaboration provides Sanofi with competitive research and development advantage with access to Rosa’s expertise in Quantitative Systems Pharmacology. 

Rosa & Co. Announces the Appointment of Matt Marano as Senior Vice President of Business Development

Rosa & Co., LLC is proud to welcome Matt Marano as the company's Senior Vice President of Business Development. Mr. Marano will be responsible for leading the continued expansion of the company's worldwide PhysioPD™ commercial strategy. Mr. Marano joins the team from SolveBio (New York, NY) where he served as Senior Vice President of Commercial Development. During his tenure at SolveBio, he directed all sales and business development efforts, specifically focusing on VP- and C-level executives within the Life Sciences industry. Prior to SolveBio, Mr. Marano was Vice President of Sales and Business Development at Gen9 (acquired by Ginkgo Bioworks), a leading next-generation gene synthesis provider, where he successfully led the organization's commercial expansion in the United States, Europe, the Middle East and Africa.

"I am thrilled to be joining the world-class team at Rosa & Co. I've focused much of my career on expanding the commercial presence of some of the Life Science industry's most impactful companies, and Rosa is truly the world leader in Quantitative Systems Pharmacology solutions for the Life Sciences industry," said Matt Marano about his appointment. "We are fortunate that an executive of Matt's stature has joined our team. Together we can further expand our ability to offer PhysioPD Research to clients world-wide," said Founder, Chairman, & CEO Ron Beaver, PhD.

prnewswire.com/news-releases/rosa--co-announces-the-appointment-of-matt-marano-as-senior-vice-president-of-business-development-300463750.html

Rosa to Present at 21st International Congress of Parkinson’s Disease and Movement Disorders Meeting

Rosa announces that Mike Reed, Chief Scientist at Rosa will present at the 21st International Congress of Parkinson’s Disease and Movement Disorders meeting on June 7th in Vancouver, BC, Canada. The poster entitled "Application of a Qualitative Model to Elucidate the Role of the Alpha-Synuclein System in Parkinson’s Disease" describes the development of a Synuclein PhysioMap®, a graphical model architecture to support hypothesis generation and testing. The Synuclein PhysioMap enabled identification of key biological uncertainties and hypotheses and the recommendation of focused laboratory experiments to gain a better understanding of synuclein function in Parkinson’s disease.

Rosa & Co to Present at SID Annual Meeting

Rosa announces that it will present two posters at the Society For Investigative Dermatology (SID) Annual Meeting on March 15th in Portland, OR. The first poster entitled " Mechanistic physiological modeling as a tool for enhancing dermatology research" describes the use of PhysioPD™ Platforms in dermatology drug research and development for acne, atopic dermatitis (AD), psoriasis, skin aging, and erythema indications will be presented by Christina Friedrich, Chief Engineer at Rosa & Co. The second poster entitled “Mechanistic modeling facilitates identification of key pathways involved in dermal aging and potential new targets for anti-aging intervention” is a joint presentation between Proctor & Gamble and Rosa & Co and will be presented by Katherine Kudrycki, Principal Scientist at Rosa. The poster describes the development of a Skin PhysioPD™ Research Platform, a quantitative physiological model representing the physiology of aged dermis and the effects of anti-aging treatments and the use of this Platform to research treatments for photoaged skin.

"I am grateful to our many clients who have challenged us over the past 15 years to conduct PhysioPD Research on the frontier of science."
—Ron Beaver, PhD, Founder, CEO
Learn more about PhysioPD